SGD-1882 是一种有细胞毒性的 DNA 小沟交联剂,为 PBD 二聚体,可以作为 ADC 的有效载荷。
产品详情
SGD-1882 是一种有细胞毒性的 DNA 小沟交联剂,为 PBD 二聚体,可以作为 ADC 的有效载荷。
生物活性
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.
性状
Solid
体外研究(In Vitro)
SGD-1882 is the cytotoxic payload undergoing clinical evaluation for anti-CD33 and anti-CD70 conjugates. SGD-1882 is not an MDR1 substrate, and SGN-CD33A is conjugated to the SGD-1882. SGN-CD33A can kill MDR1 expressing CD33 positive AML patient samples and is currently in Phase I. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
参考文献
[1]. Eunhee G. Kim, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015 Nov; 23(6): 493-509.[2]. Dowdy Jackson, et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2015; 32(11): 3458-3469.
溶解度数据
In Vitro: DMSO : 100 mg/mL (137.78 mM; Need ultrasonic)配制储备液
[1]. Eunhee G. Kim, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015 Nov; 23(6): 493-509.[2]. Dowdy Jackson, et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2015; 32(11): 3458-3469.